课题基金 / 基金详情

IL2 DEFICIENCY MEDIATES AUTOIMMUNITY IN MRL-LPR MICE

IL2 DEFICIENCY MEDIATES AUTOIMMUNITY IN MRL-LPR MICE
IL2 缺乏介导 MRL-LPR 小鼠的自身免疫
批准号:
2081787
负责人:
Ralph C Budd
金额:
$17.54万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-12-10 至 1996-11-30

项目摘要

项目成果

Ralph C Budd的其他基金

相似基金

相关文献

中文摘要
翻译
许多诱导的自身免疫模型都需要增强免疫。 对特定目标组织的反应。在区别上,自然有几个 出现系统性红斑狼疮(SLE)的小鼠模型 低反应性T淋巴细胞反应,特别是关于缺陷 IL2的生产。这一点在MRL-LPR小鼠中显著存在。这些 小鼠发展成系统性红斑狼疮的素质伴随着大量的 异常TCR-AlphBeta+CD2-B220-B220+CD4-CD-8 T细胞产生 当IL2被激活时,可以忽略不计,因此,表现得很少 增殖能力。它们类似于无能T细胞和其他 CD2-T细胞。Lpr缺陷是由fas基因突变引起的。 它介导了细胞的凋亡。这可能解释了为什么 T细胞的积聚,但不能很容易地解释发育 这些细胞的停滞,也不是信号缺陷的原因 转导,从而产生IL-2。这项提案将研究这一点 IL-2基因转录调控因子水平的缺陷。 然后,它将评估IL2在MRL体内治疗的潜在好处- LPR小鼠并监测T细胞表型和功能的变化 这可能是造成这种情况的原因。 第一个特定目的是分析IL2基因的表达调控 新鲜和培养MRL-LPR中凝胶迁移率变化的转录因子 PMA和PMA激活前后的CD4-8-、CD4+和MRL+/+T细胞 离子霉素,或抗CD3单抗。这将与刺激的T细胞进行比较 在没有或存在抗Fas单抗的情况下与抗CD3单抗结合。这 部分将定义LPR CD4-8-T细胞中IL2缺陷的性质和 帮助建立IF-FAS在IL-2共刺激中的作用 制作。第二个具体目标是延长初步的体外试验 观察到IL2可诱导细胞周期、CD2诱导、B220丢失、 LPR CD4-8-T细胞的功能增强。MRL-LPR小鼠将是 体内注射IL-2作为cDNA构建物,作为表型和 CD4-9的功能--在潜在的有益或 确定了对自身免疫过程的有害影响。
英文摘要
Many induced models of autoimmunity necessitate augmenting the immune response to a specific target tissue. In distinction, several naturally arising mouse models of systemic lupus erythematosus (SLE) manifest hyporesponsive T lymphocyte responses, particularly regarding deficient IL2 production. This is strikingly present in the MRL-lpr mouse. These mice develop an SLE diathesis accompanied by an enormous accumulation of abnormal TCR-alphBeta+ CD2- B220- B220+ CD4-CD-8 T cells that produce negligible IL2 when activated and as a result, manifest little proliferative capacity. A such they resemble anergic T cells and other CD2-T cells. The lpr defect results form a mutation of the fas gene which mediates apoptosis. This may account for the pronounced accumulation of T cells, but does not readily explain the developmental arrest of these cells, nor the reason for the defect in signal transduction and hence IL2 production. This proposal will examine this defect at the level of the IL2 gene regulatory transcription factors. It will then assess the potential benefits of IL2 in vivo therapy in MRL- lpr mice and monitor the alterations in T cell phenotype and function that may be responsible for this. The first specific aim analyzes the expression of the IL2 gene regulatory transcription factors by gel mobility shift in fresh and cultured MRL-lpr CD4-8-, CD4+, and MRL+/+ T cells before and after activation with PMA and ionomycin, or anti-CD3 mAb. This will be compared to T cells stimulated with anti-CD3 mAb in the absence or presence of anti-fas mAb. This portion will define the nature of the IL2 defect in lpr CD4-8-T cells and help establish the contribution if fas in costimulation of IL2 production. The second specific aim will extend the preliminary in vitro observation that IL2 can induce cell cycling, CD2 induction, B220 loss, and gain of function by lpr CD4-8- T cells. MRL-lpr mice will be administered IL2 in vivo as a cDNA construct, as the phenotype and function of the CD4-9- monitored while the potential beneficial or detrimental effects on the autoimmune process are determined.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Vermont Center for Immunobiology/Infectious Diseases (VCIID)
Pilot Projects
Metabolic Regulation of Caspases and Survival in T Cells
VCIID Administrative Core
海外基金